Ondansetron Tablets USP 8 mg + Ondansetron Hydrochloride

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fasting State

Conditions

Fasting State

Trial Timeline

May 1, 2011 → Sep 1, 2011

About Ondansetron Tablets USP 8 mg + Ondansetron Hydrochloride

Ondansetron Tablets USP 8 mg + Ondansetron Hydrochloride is a phase 1 stage product being developed by Ipca Laboratories for Fasting State. The current trial status is completed. This product is registered under clinical trial identifier NCT01578252. Target conditions include Fasting State.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT01578252Phase 1Completed
NCT01578265Phase 1Completed

Competing Products

20 competing products in Fasting State

See all competitors
ProductCompanyStageHype Score
Lamotrigine Tablets 25 mg + LamotrigineIpca LaboratoriesPhase 1
33
Metformin Hydrochloride Extended-Release Tablets USP 750 mg + GLUCOPHAGE®XRIpca LaboratoriesPhase 1
33
Metformin Hydrochloride Extended-Release Tablets USP 750 + GLUCOPHAGE®XR tablet 750 mgIpca LaboratoriesPhase 1
33
Quetiapine Fumarate Tablets 25 mg + Quetiapine FumarateIpca LaboratoriesPhase 1
33
Metoprolol Succinate ER Tablets 50 mg + 'TOPROL-XL®' ER Tablets 50 mgIpca LaboratoriesPhase 1
33
Etodolac Capsules USP 300 mg + EtodolacIpca LaboratoriesPhase 1
33
Risperidone Tablet 1 mg + RisperidoneIpca LaboratoriesPhase 1
33
Lisinopril and Hydrochlorothiazide Tablets (20+25) mg + Zestoretic® 20/25 lisinopril/hydrochlorothiazide TabletsIpca LaboratoriesPhase 1
33
Allopurinol + AllopurinolIpca LaboratoriesPhase 1
33
Levocetirizine Dihydrochloride 5 mg TabletsIpca LaboratoriesPhase 1
33
Etodolac Extended Release Tablets USP 600mg + Etodolac Extended Release Tablets 600mgIpca LaboratoriesPhase 1
33
Carvedilol Tablets USP 12.5 mg + CarvedilolIpca LaboratoriesPhase 1
33
Metoprolol Succinate ER Tablet 200 mg + 'TOPROL-XL®' ER Tablets 200 mgIpca LaboratoriesPhase 1
33
Etodolac Tablets USP 500mg + Etodolac Tablets USP 500 mgIpca LaboratoriesPhase 1
33
Etodolac Extended Release Tablets USP 600mg + Etodolac Extended Release Tablets 600mgIpca LaboratoriesPhase 1
33
Bisoprolol Fumarate Tablet 10 mg + BisoprololIpca LaboratoriesPhase 1
33
Lisinopril Tablets 40 mg + LisinoprilIpca LaboratoriesPhase 1
33
r-metHuLeptinAmgenPhase 1/2
40
r-metHuLeptinAmgenPhase 1
32
OlanzapineDr. Reddy's LaboratoriesPhase 1
30